Recent new data from two head-to-head studies showed Utibron Neohaler provided clinically meaningful and comparable bronchodilation to GSK's Anoro™ Ellipta® in US patients with COPD. However, the primary endpoint in terms of 24-hour lung function improvement (FEV1 AUC0-24h) was not met statistically. A full evaluation of this new data is ongoing and will be communicated in due course. The primary objectives of the two head-to-head studies were to demonstrate that Utibron Neohaler was non-inferior to Anoro Ellipta in terms of improving lung function over a 24-hour period (FEV1 AUC0-24h), after 12 weeks of treatment, more information on the trial design can be found at: Clinicaltrials.gov.
Novartis版 & Vectura版
Recent new data from two head-to-head studies showed Utibron Neohaler provided clinically meaningful and comparable bronchodilation to GSK's Anoro™ Ellipta® in US patients with COPD. However, the primary endpoint in terms of 24-hour lung function improvement (FEV1 AUC0-24h) was not met statistically. A full evaluation of this new data is ongoing and will be communicated in due course. The primary objectives of the two head-to-head studies were to demonstrate that Utibron Neohaler was non-inferior to Anoro Ellipta in terms of improving lung function over a 24-hour period (FEV1 AUC0-24h), after 12 weeks of treatment, more information on the trial design can be found at: Clinicaltrials.gov.